Actelion Integrates Product Lifecycle Management and Portfolio Management
Adapted from Actelion Pharmaceuticals Ltd.'s 2005 Best Practices entry
Short drug lifecycles, strong competition, increasing health authority hurdles, rising development costs and need for implementation of the latest technologies are putting tremendous pressure on pharmaceutical industry. Therefore, for pharmaceutical and biotechnology companies to remain competitive in the global drug market they continuously must develop a portfolio of new drugs and indication extensions to the market successful. The challenge is managing the product portfolio to reduce time-to-market and maximize return on R&D investment.
Effective product development comprises two components: Doing products right and doing the right products. While Product Lifecycle Management is all about doing products right, portfolio management is about doing the right products i.e. developing the right set of products to meet business needs and helping to deliver the results. This paper describes Actelion's integrated Product Lifecycle and Portfolio Management to support company strategy.
Project Details: Drug Discovery and Development Process
Target identification is the first step of the drug discovery and development process in which scientists search for a 'target' or a particular gene sequence that they believe might influence the course of a specific disease. An identified target helps scientists develop compounds that might interact with the target to alter how it affects a biochemical pathway and ultimately, the disease. Chemists develop compounds that may interact with that particular target. Using an automated robotics system, scientists may screen more than a million compounds to find a promising lead.
Read
More . . .
Bausch & Lomb's Product Development Management Process
Adapted from Bausch & Lomb's 2005 Best Practices entry
To accelerate and optimize global new product development efforts, Bausch & Lomb developed a standardized Product Development Management Process (PDMP) methodology, a phase-gate process that takes products from concept through feasibility, development, commercialization, and launch. This evolving methodology requires intensive collaboration among cross-functional team members, including representatives from operations, engineering, packaging, marketing, quality, regulatory affairs, and other departments. These global teams require significant project information on a daily basis—including budgets, project plans, timelines, activity tracking, lab analyses, test results, and other reports. In the past, all this information was typically exchanged using fax and e-mail, which was extremely cumbersome and inefficient. Many in-person meetings were also required, costing the company millions of dollars in travel expenses.
Within the past two years, Bausch & Lomb has rolled out across its extended global enterprise a new collaborative technology-based PDMP solution that has completely transformed the way the company develops and launches new products. By providing a seamless global product development environment that facilitates and fosters collaboration, time to market for new products has been reduced across products by an average of four to eight weeks, the portfolio of new products in development has almost tripled, and well over $1.2 million is being saved annually in reduced travel and other project-related expenses.
Background
Bausch & Lomb is the world's leading technology-based health care company for the eye, with 2004 revenues of $2.25 billion and products sold in 100 countries. The company produces vision care products in three business areas: vision care (contact lenses, lens care, and eye solutions), surgical instruments and platforms, and pharmaceuticals.
Read
More . . .